01500nam 2200361 450 991068827440332120230704203500.0(CKB)5850000000050400(NjHacI)995850000000050400(EXLCZ)99585000000005040020230704d2022 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierHepatitis B /Luis Rodrigo, editorLondon :IntechOpen,2022.1 online resource (126 pages)1-80355-008-2 Current pharmacologic therapies for chronic hepatitis B virus (HBV) infection allow viral suppression and normalization of the liver enzyme alanine aminotransferase (ALT) and prevent liver disease from progressing. The currently available antiviral therapies very rarely lead to a functional cure. Thus, the future of a cure for HBV lies in triple combination therapies with concerted action on replication inhibition, antigen reduction, and immune stimulation. This book reviews the mechanisms and pathogenesis of HBV, as well as discusses current and potential future treatments.HepatomaLiverTumorsHepatoma.LiverTumors.616.99436Rodrigo LuisNjHacINjHaclBOOK9910688274403321Hepatitis B2902988UNINA